Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1986 Feb;61(2):173–177. doi: 10.1136/adc.61.2.173

Abnormalities of vascular prostaglandins in Henoch-Schönlein purpura.

S Turi, J J Belch, T J Beattie, C D Forbes
PMCID: PMC1777583  PMID: 2420289

Abstract

The ability of plasma to support prostacyclin like activity from human umbilical arterial rings was studied in 17 patients with Henoch-Schönlein purpura and 17 controls matched for age and sex. Plasma from 13 of the 17 patients showed a diminished or absent ability to support prostacyclin like activity in vitro. Six patients whose plasma had a low or absent ability to support prostacyclin like activity showed evidence of inhibitory activity. Plasma from three of these patients also failed to preserve the effect of a stable prostacyclin like analogue (ZK36-374). The plasma concentration of prostacyclin metabolite and the serum concentration of thromboxane A2 metabolite, thromboxane B2, were measured simultaneously. The concentration of plasma prostacyclin metabolite in 10 of the 14 patients was decreased, and a positive correlation was found between the plasma prostacyclin metabolite values and the ability of the plasma to support prostacyclin like activity. There was no significant difference in the serum thromboxane A2 metabolite concentrations between the patients and controls. These data suggest that abnormalities of vascular prostaglandin metabolism are involved in the pathophysiology of Henoch-Schönlein purpura.

Full text

PDF
173

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ACKROYD J. F. Allergic purpura, including purpura due to foods, drugs and infections. Am J Med. 1953 May;14(5):605–632. doi: 10.1016/0002-9343(53)90377-5. [DOI] [PubMed] [Google Scholar]
  2. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  3. Belch J. J., Greer I., McLaren M., Saniabadi A. R., Miller S., Sturrock R. D., Forbes C. D. The effects of intravenous ZK36-374, a stable prostacyclin analogue, on normal volunteers. Prostaglandins. 1984 Jul;28(1):67–77. doi: 10.1016/0090-6980(84)90114-x. [DOI] [PubMed] [Google Scholar]
  4. Belch J. J., Greer I., McLaren M., Walker J., Forbes C. D. Measurement of prostacyclin metabolites. Lancet. 1983 Dec 24;2(8365-66):1504–1504. doi: 10.1016/s0140-6736(83)90854-1. [DOI] [PubMed] [Google Scholar]
  5. Greaves M., Preston F. E. Plasma 6-keto-prostaglandin F1alpha: fact or fiction. Thromb Res. 1982 May 1;26(3):145–157. doi: 10.1016/0049-3848(82)90135-9. [DOI] [PubMed] [Google Scholar]
  6. Habib R., Levy M. Anaphylactoid purpura nephritis: observations with sixty childhood cases. Clin Pediatr (Phila) 1973 Jul;12(7):445–446. doi: 10.1177/000992287301200815. [DOI] [PubMed] [Google Scholar]
  7. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hidaka T., Nakano M., Ueta T., Komatsu Y., Yamamoto M. Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease. J Pediatr. 1983 Jan;102(1):94–96. doi: 10.1016/s0022-3476(83)80300-x. [DOI] [PubMed] [Google Scholar]
  9. Levin M., Elkon K. B., Nokes T. J., Buckle A. M., Dillon M. J., Hardisty R. M., Barratt T. M. Inhibitor of prostacyclin production in sporadic haemolytic uraemic syndrome. Arch Dis Child. 1983 Sep;58(9):703–708. doi: 10.1136/adc.58.9.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Machin S. J., McVerry B. A., Parry H., Marrow W. J. A plasma factor inhibiting prostacyclin-like activity in thrombotic thrombocytopenic purpura. Acta Haematol. 1982;67(1):8–12. doi: 10.1159/000207018. [DOI] [PubMed] [Google Scholar]
  11. McLaren M., Belch J. J., Forbes C. D., Prentice C. R. Development of a radioimmunoassay for the measurement of prostacyclin metabolites in unextracted plasma. Thromb Res. 1985 Jan 1;37(1):177–183. doi: 10.1016/0049-3848(85)90044-1. [DOI] [PubMed] [Google Scholar]
  12. Meadow R. Schönlein-Henoch syndrome. Arch Dis Child. 1979 Nov;54(11):822–824. doi: 10.1136/adc.54.11.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mitchell M. D. A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations. Prostaglandins Med. 1978 Jul;1(1):13–21. doi: 10.1016/0161-4630(78)90072-1. [DOI] [PubMed] [Google Scholar]
  14. Moncada S., Higgs E. A., Vane J. R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977 Jan 1;1(8001):18–20. doi: 10.1016/s0140-6736(77)91655-5. [DOI] [PubMed] [Google Scholar]
  15. Remuzzi G., Marchesi D., Zoja C., Muratore D., Mecca G., Misiani R., Rossi E., Barbato M., Capetta P., Donati M. B. Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. Prostaglandins. 1980 Jul;20(1):105–110. doi: 10.1016/0090-6980(80)90010-6. [DOI] [PubMed] [Google Scholar]
  16. Remuzzi G., Misiani R., Marchesi D., Livio M., Mecca G., de Gaetano G., Donati M. B. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet. 1978 Oct 21;2(8095):871–872. doi: 10.1016/s0140-6736(78)91573-8. [DOI] [PubMed] [Google Scholar]
  17. Saldeen P., Nilsson I. M., Saldeen T. Increased synthesis of thromboxane B2 and 6-keto-PGF1 alpha in hand veins from patients with deep venous thrombosis. Thromb Res. 1983 Dec 1;32(5):461–467. doi: 10.1016/0049-3848(83)90256-6. [DOI] [PubMed] [Google Scholar]
  18. VERNIER R. L., WORTHEN H. G., PETERSON R. D., COLLE E., GOOD R. A. Anaphylactoid purpura. I. Pathology of the skin and kidney and frequency of streptococcal infection. Pediatrics. 1961 Feb;27:181–193. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES